Tailoring antiviral therapy of chronic hepatitis C to the single patient standard therapy versus treatment guided by a physic-mathematical model of the dynamics of Hepatitis C Virus infection. - Tailoring antiviral therapy by HCV dynamics

AZIENDA OSPEDALIERA PISANA0 sites240 target enrollmentMarch 23, 2007

Overview

No summary available.

Registry

who.int

Start Date

March 23, 2007

End Date

TBD

Last Updated

13 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

AZIENDA OSPEDALIERA PISANA

•Patients with chronic hepatitis C with or without cirrhosis and are either therapy na ve or were relapsers after a previous standard therapy course. Their age will range between 18 and 70 years and females have to be willing to be able to take preventive contraceptive measures during treatment and for 6 months after the end of therapy
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1\.2 Adults (18\-64 years) yes
•F.1\.2\.1 Number of subjects for this age range
•F.1\.3 Elderly (\>\=65 years) yes
•F.1\.3\.1 Number of subjects for this age range

•Pregnant or breast feeding women; Chronic liver disease with signs of portal hypertension oesophageal or gastric varices at endoscopy and or history of episodes of liver decompensation; Hepatocellular carcinoma; Subjects with organ transplant, except corneal and hair transplants; Known or suspected toxicity from standard Interferons, PEG\-Interferons or ribavirin; Treatment with any other experimental drugs within 30 days since the recruitment date; Subjects with any form of haemoglobin disease, not only major and minor talaxemia; Positive HIV sierology